The clue arrived disguised as a spreadsheet. Jennifer Kyle had been called by a publicly traded biotech company to clean up its clinical accruals, connect those numbers to financial planning and strengthen the controls around the process. She built a comprehensive workbook. It did its job well enough that another biotech wanted something similar. Then another. The spreadsheet, one imagines, should have started invoicing for travel.
Kyle had already seen finance from several useful angles. She began in audit, including work with biotech companies and IPOs at EY. She moved into finance and operations leadership, with roles at PIRCH and Gerrity Group. Then she became a consultant, taking on the sort of backlog projects that sit between departments because no single department quite owns them. She liked that territory. It was where accounting rules, operating reality and financial planning had to agree.
Her original plan had been tidier: leave audit, climb the corporate ladder and become a CFO. Yet the work that held her attention was less about occupying the corner office than repairing the plumbing behind it. “I loved making business processes more efficient and effective,” she later said in an interview. She called that ability her superpower. The phrase is cheerful; the work itself involved controls, contracts, reconciliations and the solemn little mysteries hidden in a workbook's twentieth tab.
01 / The accidental categoryThe problem that kept introducing itself
The recurring assignment concerned clinical finance, a function with a difficult translation job. Clinical teams monitor protocols, sites, enrollment and vendor activity. Finance teams need budgets, forecasts, accruals and explanations of variance. Accounting needs a close it can defend. The information exists, but it tends to arrive from different systems, in different formats, on different clocks.
The translation job inside clinical finance
Kyle spoke with large pharmaceutical companies and smaller biotechs. The larger organizations often built homegrown databases; the smaller ones leaned on Excel. The surface tools differed, but she found the same basic problem: fragmented data and a process few people could explain from end to end. This is how a niche announces itself. It does not send a brass band. It sends the same ugly task three times.
“I didn't go looking for this, it found me pretty organically.”Jennifer Kyle, on finding the problem behind Condor
By Kyle's account, the conclusion became difficult to avoid. There was a market, and someone would build for it. “So, I said, ‘Why not? Let's do it.’” Her career moved from accounting to finance, then consulting, then software. Condor was founded in 2020 to turn the bespoke workbook into a shared system for clinical and financial teams.
02 / The auditor's advantageMake the number traceable before making it clever
Vertical software often begins with a peculiar form of respect. The founder has to respect the boring parts that outsiders would simplify away. In clinical finance, an accrual is not merely a number waiting to be automated. It may depend on patient activity, contract terms, vendor reporting, timing assumptions and accounting policy. A useful system has to preserve why the number exists.
Her preparation for that work was conventional in the useful sense. Kyle graduated from the University of South Florida with a bachelor's degree in business management and an emphasis in economics. She earned a California CPA credential in 2014. Audit trained her to follow evidence backward; operating roles taught her that the evidence is usually created by people with other priorities. The product founder had to hold both ideas at once. A number must survive inspection, but the people supplying it still need a workflow they will use on an ordinary Tuesday.
Kyle's audit background shows up in Condor's product language: controls, traceability, reconciliations and a reliable record. Its platform is organized around three modules. Connect brings clinical and financial data together. Compass forecasts cost and models changing scenarios. Copilot automates accruals, reconciliation and monthly-close work. The names are polished; the deeper bet is procedural. Software earns trust by remembering the route from raw activity to reported figure.
That concern becomes sharper as AI enters finance. Kyle has argued publicly for a deterministic core where budgets, patient-enrollment curves and site performance are calculated, with AI layered above it to analyze patterns and explain changes. In her framing, material outputs still require human review. The arithmetic should be auditable; the machine can help with interpretation. It is an accountant's answer to a fashionable technology, which may be why it sounds less fashionable and more usable.
She has also become a translator in public. Kyle has joined industry congresses, interviews and webinars with PwC and BDO professionals to discuss accounting, forecasting, controls and software selection. On the Accounting Life podcast, she traced the move from auditor to biotech CEO. These appearances share a practical vocabulary. She talks about the thing that breaks, the person who has to reconcile it and the decision delayed while everyone waits. Thought leadership is a grand name for explaining why a change order has ruined someone's afternoon, but the specificity is the point.
03 / Finance as fieldworkThe forecast is only as good as its contact with reality
Kyle's public explanations of FP&A dwell on fragmentation and movement. Trial enrollment slips. Protocols change. Site costs exceed estimates. Vendor invoices lag the work. A budget that looked precise in January can become historical fiction by June. The old response was periodic reconciliation: gather the files, compare the versions and ask everyone what changed. The newer ambition is continuous planning, in which operational activity updates the financial view while decisions can still change.
This is not merely a faster accounting close. It changes the conversation between functions. Finance can see the operational drivers behind a variance. Clinical teams can see the financial consequence of a timeline change. Leadership can model the cost of accelerating, delaying or resizing a program without waiting for a new stack of workbooks. The stealable idea in Kyle's approach is straightforward: do not begin with the dashboard. Begin with the translation layer that lets each department recognize its own reality in the same system.
What Condor says customers report
Company-reported outcomes announced with the March 2026 financing
The economic argument reaches beyond office efficiency. Kyle has connected unpredictable development costs to the pressure on drug pricing and to decisions about which research programs continue. Her emphasis is on visibility: understand the complete portfolio cost, know what has been committed and identify financial risk before a stale forecast becomes a surprise. Condor's product sits in that narrow but consequential interval between the work happening and management realizing what it costs.
04 / The scale-upTwenty-four million dollars for a clearer view
In March 2026, Condor announced a $24 million Series A led by Insight Partners, with participation from Felicis, 645 Ventures, Pamir Ventures, SNR Ventures, Prebys Ventures and Bramalea Partners. The company said the round brought total funding to $36 million. It also reported that its platform managed more than $19 billion in R&D spend for customers including Acadia Pharmaceuticals, Alumis Therapeutics, BridgeBio Pharma and Madrigal Pharmaceuticals.
The capital is meant to expand the platform, strengthen enterprise capabilities and grow the engineering, product, design, sales and customer-success teams. For Kyle, this introduces a second translation problem: how to turn founder knowledge into an organization. Her own maxim is compact: “The team we build is the company that we build.” In the summer of 2026, she wrote that Condor had more than doubled in size since March. She described weeks of travel to meet teammates, customers and partners, and the moment when growth stopped being a headcount chart and became coffee with a new colleague.
That detail fits her path. Kyle's career has advanced through proximity to the work: auditing the books, running finance, rebuilding a process, sitting with clients, then encoding what she learned. Even Condor's current AI push is presented through workflows rather than spectacle. Its webinar series demonstrates change-order review, investigator-grant discrepancies and accrual risk. The unit of progress is a job completed with better context.
“Conviction before consensus is one of the most valuable investments anyone can make.”Jennifer Kyle, writing about early backers
05 / What comes nextThe intelligence layer under the budget meeting
Kyle now describes the ambition as a financial intelligence layer for life-sciences R&D. The phrase is larger than accrual automation. It means a system that can connect clinical activity with contracts, invoices and accounting rules; explain why a number moved; and let teams test scenarios before a decision hardens. In August 2026, she teased a forthcoming Condor announcement around an engine-built financial truth, AI-run workflows and explanations available in seconds.
There is an appealing symmetry to the story. Kyle left audit because she thought she wanted the top finance job. She found a better fit in the joins between jobs, then built a company around those joins. Accounting met operations. Clinical data met finance. Deterministic calculation met AI interpretation. The awkward spaces between departments became the product.
Plenty of founder stories begin with an ambition and go searching for a problem. Kyle's began with a problem persistent enough to revise the ambition. The workbook kept returning because the underlying need had nowhere else to live. Condor is her attempt to give it a proper address, an audit trail and, at long last, fewer tabs.